loading
Rigel Pharmaceuticals stock is traded at $20.17, with a volume of 164.01K. It is down -1.27% in the last 24 hours and up +8.27% over the past month. Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
See More
Previous Close:
$20.43
Open:
$20.54
24h Volume:
164.01K
Relative Volume:
0.84
Market Cap:
$360.49M
Revenue:
$116.88M
Net Income/Loss:
$-25.09M
P/E Ratio:
-144.07
EPS:
-0.14
Net Cash Flow:
$-20.74M
1W Performance:
+7.29%
1M Performance:
+8.27%
6M Performance:
-9.02%
1Y Performance:
+85.05%
1-Day Range:
Value
$20.00
$20.64
1-Week Range:
Value
$18.80
$21.38
52-Week Range:
Value
$8.61
$29.82

Rigel Pharmaceuticals Stock (RIGL) Company Profile

Name
Name
Rigel Pharmaceuticals
Name
Phone
650-624-1100
Name
Address
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Name
Employee
164
Name
Twitter
@rigelpharma
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
RIGL's Discussions on Twitter

Compare RIGL with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
RIGL
Rigel Pharmaceuticals
20.17 365.13M 116.88M -25.09M -20.74M -0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-03-23 Resumed Piper Sandler Neutral
Jun-09-22 Downgrade Citigroup Buy → Neutral
Jun-08-22 Downgrade Cantor Fitzgerald Overweight → Neutral
Jun-08-22 Downgrade Piper Sandler Overweight → Neutral
Mar-23-22 Initiated B. Riley Securities Neutral
Nov-09-20 Downgrade JP Morgan Overweight → Neutral
Nov-15-19 Resumed Cantor Fitzgerald Overweight
Sep-26-19 Resumed JP Morgan Overweight
Mar-01-19 Reiterated Cantor Fitzgerald Overweight
Aug-27-18 Initiated Citigroup Buy
May-02-18 Reiterated Cantor Fitzgerald Overweight
Dec-21-17 Resumed Piper Jaffray Overweight
Dec-15-17 Initiated Cantor Fitzgerald Overweight
Nov-06-17 Resumed H.C. Wainwright Buy
Mar-09-17 Reiterated H.C. Wainwright Buy
Aug-31-16 Reiterated H.C. Wainwright Buy
Aug-30-16 Reiterated Piper Jaffray Overweight
Jul-13-16 Initiated H.C. Wainwright Buy
Jun-13-16 Initiated Piper Jaffray Overweight
Apr-22-16 Upgrade JP Morgan Neutral → Overweight
Apr-08-13 Reiterated Stifel Buy
Nov-29-12 Initiated UBS Neutral
Nov-06-12 Reiterated Oppenheimer Outperform
Mar-26-12 Initiated Canaccord Genuity Hold
Dec-10-10 Downgrade MP Advisors Outperform → Market Perform
View All

Rigel Pharmaceuticals Stock (RIGL) Latest News

pulisher
Jul 25, 2025

Eli Lilly and Rigel Pharmaceuticals: Promising Advances in Rheumatoid Arthritis Treatment - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

Will Rigel Pharmaceuticals Inc. stock benefit from AI tech trendsHigh-impact stock picks - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

Is Rigel Pharmaceuticals Inc. a good long term investmentAccelerated wealth building - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 25, 2025

What institutions are buying Rigel Pharmaceuticals Inc. stock nowHigh-margin investment plays - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 24, 2025

What analysts say about Rigel Pharmaceuticals Inc. stockStrongest growth potential - PrintWeekIndia

Jul 24, 2025
pulisher
Jul 24, 2025

What drives Rigel Pharmaceuticals Inc. stock priceHigh-margin investment plays - Autocar Professional

Jul 24, 2025
pulisher
Jul 24, 2025

Institutional investors have a lot riding on Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) with 65% ownership - simplywall.st

Jul 24, 2025
pulisher
Jul 23, 2025

Eli Lilly and Rigel Pharmaceuticals Advance Rheumatoid Arthritis Study with LY3871801 - TipRanks

Jul 23, 2025
pulisher
Jul 22, 2025

Rigel Pharmaceuticals Inc. Stock Analysis and ForecastFastest-growing stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 20, 2025

(RIGL) Proactive Strategies - news.stocktradersdaily.com

Jul 20, 2025
pulisher
Jul 15, 2025

What makes Rigel Pharmaceuticals Inc. stock price move sharplyHigh Potential Stock Ideas - newser.com

Jul 15, 2025
pulisher
Jul 15, 2025

Why Rigel Pharmaceuticals Inc. stock attracts strong analyst attentionFree Top-Rated Stock Analysis - Newser

Jul 15, 2025
pulisher
Jul 10, 2025

H.C. Wainwright Reiterates a Buy Rating on Rigel Pharmaceuticals (RIGL) - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

(RIGL) Long Term Investment Analysis - news.stocktradersdaily.com

Jul 10, 2025
pulisher
Jul 07, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | RIGL Stock News - GuruFocus

Jul 07, 2025
pulisher
Jul 07, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - 富途牛牛

Jul 07, 2025
pulisher
Jul 07, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NA - GuruFocus

Jul 07, 2025
pulisher
Jun 18, 2025

Recent 11% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 112% over 1 year - simplywall.st

Jun 18, 2025
pulisher
Jun 14, 2025

Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential By Investing.com - Investing.com Canada

Jun 14, 2025
pulisher
Jun 14, 2025

Rigel Pharmaceuticals’ SWOT analysis: promising pipeline drives stock potential - Investing.com

Jun 14, 2025
pulisher
Jun 11, 2025

High-grade Glioma Market Expected to Experience Major Growth by 2034, According to DelveInsight | Rigel Pharma, Orbus Therapeutics, BioMimetix, Bayer, MedImmune, DNAtrix, Chimerix, CNS Pharma - Barchart.com

Jun 11, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Makes New Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Sold by Nuveen Asset Management LLC - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Investments LP Makes New $1.03 Million Investment in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Takes $1.19 Million Position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Rigel Pharmaceuticals at Jefferies Conference: Strategic Growth and Innovation - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Rigel Pharma To Present At Jefferies Global Healthcare Conference; Webcast At 12:50 PM ET - Nasdaq

Jun 04, 2025
pulisher
Jun 02, 2025

Deutsche Bank AG Increases Holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World

Jun 02, 2025
pulisher
Jun 02, 2025

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Average Rating of “Hold” from Brokerages - Defense World

Jun 02, 2025
pulisher
May 29, 2025

Is Rigel Pharmaceuticals (RIGL) Stock Undervalued Right Now? - Yahoo Finance

May 29, 2025
pulisher
May 29, 2025

Rigel to Present at the Jefferies Global Healthcare Conference - StreetInsider

May 29, 2025
pulisher
May 28, 2025

Director Lapointe Anthony Gregg was granted 2,500 shares, increasing direct ownership by 25% to 12,500 units (SEC Form 4) - Quantisnow

May 28, 2025
pulisher
May 28, 2025

Director Hannah Alison L. was granted 2,500 shares, increasing direct ownership by 31% to 10,625 units (SEC Form 4) - Quantisnow

May 28, 2025

Rigel Pharmaceuticals Stock (RIGL) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Rigel Pharmaceuticals Stock (RIGL) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Schorno Dean L
EVP & Chief Financial Officer
Feb 05 '25
Sale
21.93
1,734
38,020
57,235
Santos David A
EVP, Chief Commercial Officer
Feb 04 '25
Sale
20.92
2,125
44,457
53,500
Santos David A
EVP, Chief Commercial Officer
Feb 05 '25
Sale
21.93
1,796
39,379
51,704
RODRIGUEZ RAUL R
CEO, President
Feb 04 '25
Sale
20.92
4,952
103,601
243,854
RODRIGUEZ RAUL R
CEO, President
Feb 05 '25
Sale
21.93
4,400
96,474
239,454
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Feb 04 '25
Sale
20.92
1,448
30,294
40,169
Furey Raymond J.
EVP, GC, CCO & Corp Sec
Feb 05 '25
Sale
21.93
1,339
29,359
38,830
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Cap:     |  Volume (24h):